CRF Health’s TrialMax® Platform Selected to Support Global Development of New Diabetes Treatment
Plymouth Meeting, PA – March 17 2016: CRF Health, the leading global provider of eCOA solutions for the life sciences industry, today announced its TrialMax® eCOA platform has been selected by a leading sponsor in the field of diabetes research. The solution will accelerate the collection of data through a third party medical device in support of a Phase III program of work encompassing multiple clinical trial protocols.
Furthering the company’s existing expertise in this therapeutic area, this latest program will see TrialMax used to capture more than 4.6 million data points via an integrated medical device. More than 3,000 patients across 450 sites in 28 countries will benefit from real-time integration of their diabetes care devices and patient diaries. Leveraging the solution will enable the program to be conducted faster by monitoring patients in real-time, while creating uniformity in reporting processes across the program’s individual studies.
CRF Health’s TrialMax Touch® handheld patient eDiary and TrialMax Slate® tablet solution will work together to bring increased insight into patient reported outcomes by delivering efficient and unobtrusive data collection. Using its collaborative design tool, TrialStudio®, CRF Health has worked in conjunction with the sponsor to create an innovative design which meets the specific protocol needs of diabetes and will enable its investigators to achieve more accurate and efficient data collection.
Commenting on the agreement, John Blakeley, Chief Business Officer at CRF Health, said: “Having collaborated previously to deliver numerous trials across multiple therapeutic areas, this latest program of work shows the confidence the sponsor has in our technology platform as well as our highly collaborative process to deliver results, and is evidence of the continued strength of our relationship. Our experience and proven track record in providing specific eCOA solutions for diabetes trials makes CRF Health ideally placed to deliver these important studies, and we are proud to have a part in developing better treatments for those living with this condition.”
For further information on CRF Health's eCOA platform for diabetes trials, please visit www.crfhealth.com.
About CRF Health
CRF Health is the leading provider of electronic Clinical Outcome Assessment (eCOA) solutions for global clinical trials. With experience in more than 650 trials, over 100 languages and across 74 countries, CRF Health’s TrialMax® eCOA solutions consistently demonstrate the industry’s highest data accuracy, patient and site compliance, and patient retention.
CRF Health’s TrialMax eCOA solutions improve trial engagement by fitting into the lives of patients and seamlessly integrating into sites to maximize protocol compliance. Their eCOA solutions include PROs (Patient Reported Outcomes), ObsROs (Observer Reported Outcomes) and ClinROs (Clinician or Rater Reported Outcomes).
Contact: media@crfhealth.com, +1 267.498.2350
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
